Explore the Agenda
7:45 am Check-In & Morning Coffee
9:00 am Program Director’s Opening Remarks
9:05 am Chair’s Opening Remarks
Pioneering Platforms to Discover & Optimize Novel PROTACs & Covalent Degraders to Drug the Undruggable
9:15 am Targeting ‘Undruggable’ Targets: Pioneering Novel Applications of Heterobifunctional Degraders – An Update
- Outlining the Astellas’ approach to targeted protein degradation
- Updating on the progress of Setidegrasib (ASP3082) and next-generation degrader candidates in the pipeline
- Introducing Astellas’ integrated R&D model combining in-house discovery, translational science, and external innovation to accelerate progress
9:45 am Reimagining Druggability Using Chemoproteomic Platforms
- Evaluating covalent destabilizing degraders against undruggable transcription factors
- Exploring a rational design of both degradative and non-degradative molecular glues against undruggable transcription factors
- Discussing the development of novel induced proximity approaches for targeted transcriptional repression
10:15 am Discovery of a VHL-Based Molecular Glue Degrader Targeting GEMIN3 Using Picowell RNA-Sequencing
- Leveraging ultra-miniaturized microfluidics devices to facilitate unbiased RNA-seq screening of a biased E3-focused library to enable target-agnostic discovery of VHL MGDs
- Identifying dGEM3, a novel VHL molecular glue that targets the survival of motor neuron (SMN) complex member GEMIN3 for degradation
- Characterizing the GEMIN3 degron within its helicase ATP-binding domain and revealing how ternary complex kinetics impact degradation through cellular, biochemical, and biophysical assays
- Explaining how these findings provide insights into the re-programmability of VHL for novel targets using drug-like molecular glues
10:45 am Refreshment Break
11:00 am Networking Sessions
This is your opportunity to have face-to-face conversations with fellow attendees of the World Targeted Therapeutics Summit South Korea by Hanson Wade. Progress your TPD candidates forward and make connections with global pharma and biotech working on TPD and induced proximity, antibody-drug conjugates, bispecifics, and T-Cell engagers, as well as global service providers, in a mix of pre-organized and ad-hoc networking.
Accelerating the Clinical Translation of First-in-Class Molecular Glues & Degrader Modalities to Broaden Target Space & Help Patients Faster
11:30 am Showcasing Safety, Pharmacokinetic & Efficacy Data in Phase 1b Trials in Humans & Phase 2 Trials in Canines for the Tau Aggregate Degrader ATB2005A
- Introducing the AUTOTAC platform and its mechanism-of-action
- Discussing ATB2005A as a first-in-class Tau aggregate degrader
- Revealing detailed clinical data on ATB2005A
12:00 pm Showcasing Safety, Pharmacokinetic & Efficacy Data in Phase 1b Trials in Humans & Phase 2 Trials in Canines for the Tau Aggregate Degrader ATB2005A
- Introducing the AUTOTAC platform and its mechanism-of-action
- Discussing ATB2005A as a first-in-class Tau aggregate degrader
- Revealing detailed clinical data on ATB2005A
12:30 pm Deeper & Broader Impact Across B-Cell Malignancies With Ubx-303-1, A First-In-Class Btk/Hck/Lyn Degrader in Phase 1a
- Exploring how UBX-303-1 is a first-in-class, oral BTK/HCK/LYN degrader in Phase 1a for B-cell malignancies, demonstrating complete tumor regression in preclinical models and early signs of tumor response in the clinic
- Discussing how UBX-303-1 addresses key unmet medical needs by overcoming BTK inhibitor resistance in CLL and has the potential to introduce an oral treatment option for DLBCL patients
- Outlining how Ubix is advancing beyond CRBN-based degraders, expanding into Degrader-Antibody Conjugates (DACs) and novel E3 ligase binders
1:00 pm Lunch
1:45 pm Networking Break
This is your opportunity to have face-to-face conversations with fellow attendees of the World Targeted Therapeutics Summit South Korea by Hanson Wade. Progress your TPD candidates forward and make connections with global pharma and biotech working on ADCs, targeted protein degradation, induced proximity, bispecifics, and T-Cell engagers, as well as global service providers, in a mix of pre-organized and ad-hoc networking.
Uncovering the Mechanistic Kinetics of Molecular Glue Action to Enable Predictive Design & Guide Clinical Candidate Selection for Degraders
2:30 pm Unveiling the Dynamics of Substrate Recruitment & Release in Molecular Glue Degraders
- Exploring mechanistic insights into substrate recruitment and release to reveal how molecular glue degraders orchestrate target engagement for improved selectivity and therapeutic precision
- Demonstrating advanced experimental approaches that uncover dynamic interactions within glue-induced complexes to accelerate rational design and optimize degrader performance
- Translating structural and kinetic learnings into predictive models that streamline discovery workflows and enable faster progression of innovative gluebased therapies
3:00 pm Discovery of the Clinical Candidate CYRS1542: A Potent, Orally Available, & Well-Tolerated GSPT1 Molecular Glue Degrader Guided by Neuroendocrine Cancer Sensitivity
- Analyzing how CYRS1542 exhibits favorable ADME/PK properties with no apparent DDI liabilities and demonstrates potent antitumor activity in preclinical CDX and PDX models
- Exploring how neuroendocrine features, including high CRBN expression, are associated with increased sensitivity to CYRS1542, providing the rationale for focusing clinical development on patients with neuroendocrine cancers (e.g., SCLC, NEPC)
- Evaluating how CYRS1542 showed a broader in vitro therapeutic index and a favorable safety profile in GLP monkey toxicology studies, with no evidence of thrombocytopenia, supporting the initiation of the first-in-human study in December 2025
3:30 pm Refreshment Break & Poster Session
Contribute to the conversation and showcase your groundbreaking research in TPD and induced proximity drug discovery and development.
Driving Novel Degrader Programs From Discovery Through Preclinical Validation Across Autoimmune, Inflammation & Oncology Indications
4:30 pm Identification of Highly Potent & Selective VAV1 Molecular Glue Degrader HC118
- Exploring how VAV1 is an emerging first in class target for autoimmune and chronic inflammatory indications
- Outlining how HC118 is an orally available molecular glue degrader that is highly potent and selective targeting VAV1
- Discovering how HC118 is highly efficacious in multiple animal models and demonstrated good preclinical safety profile
5:00 pm From Discovery to Preclinical Validation of a Novel BRD4 Degrader, MT-4561
- Leveraging a proprietary TPD platform to rapidly discover potent degraders targeting BRD4
- Discussing lead optimization to achieve durable anti-tumor efficacy in diverse cancer models and patient-derived cells
- Presenting preclinical pharmacology insights to support clinical development
5:30 pm Development of a TRK-Targeting Degrader for Cancer & Pain Indications
- Discovering a potent and selective pan-TRK degrader
- Presenting preclinical validation of the TRK degrader in cancer models
- Discussing preclinical validation of the TRK degrader in pain models